We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Notice for lumasiran (Alnylam Australia Pty Ltd)
Active ingredients
lumasiran
Sponsor
Date of review outcome
Lapse date
Type
Orphan Drug
Dosage form(s)
Solution for injection
Indication
Treatment of patients with Primary Hyperoxaluria Type 1 (PH1)
Therapeutic area
Inherited metabolic disorders